Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company that regularly issues news on its drug discovery platform, clinical programs, and strategic collaborations. The company emphasizes its predictive AI/ML-powered computational discovery platform, Unigen™, which it uses to identify novel drug targets and biological pathways for immuno-oncology therapies.
News about Compugen often highlights progress across its key clinical-stage assets. Updates include data and trial milestones for COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and COM902, a potential best-in-class Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development. The company also reports on GS-0321 (previously COM503), a potential first-in-class, high-affinity anti-IL-18 binding protein antibody licensed to Gilead, and on rilvegostomig, a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca under license from Compugen.
Investors following CGEN news can expect coverage of clinical trial initiations and updates, such as the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer, pooled analyses of Phase 1 trials in platinum-resistant ovarian cancer, and first-in-human studies of GS-0321 in advanced solid malignancies. Company communications also describe partner-led studies of rilvegostomig in indications including non-small cell lung cancer and bladder cancer.
In addition, Compugen’s news flow includes quarterly financial results, cash runway commentary, amendments to collaboration agreements such as royalty monetization transactions with AstraZeneca, and participation in scientific and investor conferences. The CGEN news page on Stock Titan aggregates these announcements so readers can track clinical, financial, and partnership developments from a single source.
Compugen Ltd. (NASDAQ: CGEN) announced promising preliminary data on its drug COM701 in combination with nivolumab for treating metastatic MSS-CRC patients. The study shows a 12% overall response rate in patients with liver metastases, a significant improvement over historical rates of 0% for similar therapies. Translational data reveal strong immune activation in the tumor microenvironment, indicating a potential breakthrough for this typically non-responsive cancer. The company plans further clinical evaluations and will present detailed findings at the SITC meeting on November 10, 2022.
Compugen Ltd. (NASDAQ: CGEN) received a notification from Nasdaq on October 31, 2022, stating that its ordinary shares failed to maintain the minimum bid price of $1.00 for 30 consecutive business days, as required by Nasdaq Listing Rule 5450(a)(1). The company has a compliance period of 180 days, until May 1, 2023, to regain compliance. If the bid reaches $1.00 for 10 consecutive days before this date, compliance will be confirmed. Failure to comply may lead to delisting, but the company can appeal and possibly receive an additional grace period.
Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2022 financial results on November 14, 2022, before U.S. market opening. Management will host a conference call at 8:30 AM ET to discuss the results and provide a corporate update, including data to be presented at the Society for Immunotherapy of Cancer meeting from November 8-12, 2022. Compugen focuses on cancer immunotherapy, developing products like COM701 and COM902, and has partnered with Bayer and AstraZeneca on other programs.
Compugen Ltd. (Nasdaq: CGEN) announced new clinical data presentations for COM701 and its combinations at the ESMO-IO congress from December 7-9, 2022, in Geneva. Key presentations include findings on the triple blockade of the DNAM-axis in platinum-resistant ovarian cancer, and COM701's use in metastatic NSCLC patients previously treated with PD-1/PD-L1 inhibitors. These results aim to highlight the antitumor activity of Compugen's therapeutic candidates, advancing their immuno-oncology pipeline.
Compugen Ltd. (Nasdaq: CGEN) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10-12, 2022, in Boston, MA. The company will present new clinical data from the COM701/nivolumab cohort expansion study for metastatic MSS-CRC, highlighting preliminary antitumor activity. Additionally, research on PVRIG, a novel T cell checkpoint, will be presented. Presentation details include two oral sessions on November 10 and 11, featuring abstract numbers 659 and 504, respectively. More information will be available on Compugen's website post-event.
Compugen Ltd. (CGEN) provided an update to shareholders on September 22, 2022, highlighting strong fundamentals despite market challenges. The company is prioritizing indications with the highest chance of success and has sufficient cash flow to operate into 2024. Data shows promising anti-tumor activity for COM701 in ovarian cancer and upcoming data for COM701/nivolumab in MSS-CRC by Q4 2022. Compugen announced a strategic focus on triple combinations in its pipeline, including COM701 and COM902, while maintaining a solid balance sheet with no debt.
Compugen Ltd. (Nasdaq: CGEN) has appointed Alberto Sessa as the new Chief Financial Officer (CFO), effective November 1, 2022. Sessa brings over 30 years of experience in finance, including roles in leading financing, investor relations, and business development. His previous positions include acting CFO at several startups and CFO at Allot, where he contributed to the company's growth. This leadership change aims to bolster Compugen's strategic ambitions and enhance stakeholder value as the company accelerates its cancer immunotherapy pipeline.
Compugen Ltd. (Nasdaq: CGEN) has announced that Yaron Turpaz, Ph.D., Senior Vice President and Senior Advisor, will speak at the Fierce Biotech Summit on September 20, 2022, in Boston. The panel discussion will focus on leveraging artificial intelligence (AI) and machine learning (ML) to enhance drug discovery and development. Compugen specializes in cancer immunotherapy and has developed two proprietary product candidates: COM701 and COM902. Additional details about the event can be found here.
Compugen Ltd. (CGEN) announced the Japan Patent Office granted a new patent for its anti-PVRIG antibody, COM701, which expands its intellectual property coverage to include Japan. The patent, No. 2017-562952, safeguards COM701's composition and use, enhancing its existing patents in the U.S. and Europe. This strategic move is aimed at solidifying the company's position in the competitive cancer immunotherapy market. With a patent expiration date set for no earlier than 2036, Compugen is poised to leverage this protection as it advances its innovative pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced the granting of a new patent from the European Patent Office for anti-PVRIG antibodies aimed at cancer treatment. The patent, European Patent No. 3 653 221, secures broad protection for the use of COM701, expanding its application to any anti-PVRIG antibody that activates T and NK cells. The patent is set to expire no earlier than February 2036. This strategic move enhances Compugen’s position in the competitive cancer immunotherapy market and supports its ongoing clinical programs targeting multiple immune checkpoints.